Regulatory T Cell Therapies Become Standard Autoimmune Treatment
Building on the laureates' discoveries, engineered regulatory T cell therapies move from trials to standard treatment for multiple sclerosis, type 1 diabetes, lupus, and rheumatoid arthritis within 5-10 years. Sakaguchi's recent work improving induced Treg stability—keeping Foxp3 expression high for six weeks instead of days—makes adoptive cell therapy practical. CAR-Treg cells targeting specific antigens show particular promise: a single infusion restricts autoantibody generation in lupus models. The challenge: manufacturing costs and ensuring long-term Treg survival in hostile inflammatory environments. Success would transform 50 million American lives currently managing autoimmune conditions with immune suppressants that leave patients vulnerable to infections.
